

Methodological Note – SUN Pharma UK Ltd disclosure 2024

Introduction

SUN Pharma UK Ltd, is a wholly owned subsidiary of SUN Pharma (Netherlands) B.V, whose ultimate parent company is SUN Pharmaceutical Industries Ltd, incorporated in India. This disclosure submission relates solely to the UK operation of SUN Pharma UK Ltd. In collecting and preparing the information to be used in the submission of transfers of value to Health Care Professional's (HCP's), Other Relevant Decision makers (ORDM's) and Health Care Organisations (HCO's), SUN Pharma UK Ltd (SUN Pharma) setup the following processes.

Consent methodology

Consent was established as part of the consulting agreement (part 2.6 of the agreement 'Disclosure of payments'). All consulting agreements are stored electronically by SUN Pharma. There were no HCP transfers of value without consent to disclose.

UK HCPs have the right to withdraw consent at any time. If SUN Pharma receives such a withdrawal of consent, SUN Pharma will, within a reasonable period, move the relevant transfer of value (ToV) data into the aggregate category.

HCO consent is not required to disclose ToVs against named organisations in the UK.

Disclosure of benefits in kind to HCOs

For the HCOs that were recipients of a benefit in kind services from SUN Pharma, the cash value of the services excluding VAT was calculated and disclosed.

Patient Organisations (POs)

There were no payments to POs to disclose for 2024.

Research and development

There were no research and development payments to disclose for 2024.

Considerations

All payments to HCPs and HCOs were made in full to the recipients. It is the responsibility of the recipients to declare payments to the HMRC for tax purposes.

Currency Conversion

All payments were made in GBP.

Multi-year Contracts

No multi-year contracts are in place.

Working with Other Pharmaceutical Companies

SUN Pharma UK Ltd does not work jointly with other pharmaceutical companies.